Trinity Biotech (NASDAQ: TRIB) is one of 25 publicly-traded companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare Trinity Biotech to related businesses based on the strength of its analyst recommendations, valuation, risk, earnings, dividends, profitability and institutional ownership.
This is a breakdown of current ratings and recommmendations for Trinity Biotech and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Trinity Biotech Competitors||102||373||571||19||2.48|
This table compares Trinity Biotech and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Trinity Biotech Competitors||-885.83%||-65.54%||-25.27%|
Risk and Volatility
Trinity Biotech has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Trinity Biotech’s peers have a beta of 1.44, suggesting that their average share price is 44% more volatile than the S&P 500.
Insider and Institutional Ownership
62.1% of Trinity Biotech shares are owned by institutional investors. Comparatively, 52.8% of shares of all “Diagnostic substances” companies are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by insiders. Comparatively, 13.2% of shares of all “Diagnostic substances” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Trinity Biotech and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Trinity Biotech||$99.14 million||$2.30 million||19.12|
|Trinity Biotech Competitors||$308.35 million||$13.85 million||-44.75|
Trinity Biotech’s peers have higher revenue and earnings than Trinity Biotech. Trinity Biotech is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
About Trinity Biotech
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes. It also develops, manufactures, and distributes products in the enzyme-linked immunosorbent, western blot, and cytotoxicity assay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. Further, it offers Uni-Gold S. pneumoniae, Uni-Gold Legionella, Uni-Gold C. difficile, and Uni-Gold Syphilis products. The company sells its products through its direct sales force in the United States; and a network of independent distributors and strategic partners internationally. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.